Search results
AbbVie (ABBV) Gets FDA Rejection for Parkinson's Candidate
Zacks via Yahoo Finance· 1 year agoAbbVie ABBV announced that FDA has issued a complete response letter (CRL) to its new drug...
AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 1 year agoAbbVie's (ABBV) Q4 performance will likely reflect strong drug demand from its immunology and...
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication
Zacks via Yahoo Finance· 2 years agoAbbVie Inc. ABBV announced that the European Medicines Agency’s Committee for Medicinal Products for...
AbbVie (ABBV) to Boost Immunology Pipeline With New Acquisition
Zacks via Yahoo Finance· 2 years agoAbbVie Inc. ABBV recently announced that it has acquired UK-based private biotech, DJS Antibodies...
Can AbbVie (ABBV) Protect Revenues After Humira Patent Loss?
Zacks via Yahoo Finance· 10 months agoAbbVie’s ABBV key blockbuster immunology medicine, Humira lost patent protection in the United...
AbbVie (ABBV) Beats Q4 Earnings Estimates, Misses on Sales
Zacks via Yahoo Finance· 1 year agoAbbVie Inc. ABBV reported adjusted earnings of $3.60 per share for the fourth quarter of 2022,...
Will AbbVie's (ABBV) New Drugs Continue to Drive Q4 Earnings?
Zacks via Yahoo Finance· 1 year agoAbbVie’s ABBV fourth-quarter revenues are likely to be driven by revenues generated from the sales...
AbbVie (ABBV) to Acquire Cerevel Therapeutics (CERE) for $8.7B
Zacks via Yahoo Finance· 6 months agoAbbVie ABBV has announced a definitive agreement to acquire neuroscience drugmaker, Cerevel...
AbbVie (ABBV) Outperforms Industry This Year So Far: Here's Why
Zacks via Yahoo Finance· 2 years agoAbbVie (ABBV) has several new drugs with the potential to drive revenues once Humira loses U.S....
AbbVie (NYSE:ABBV) shareholders have earned a 14% CAGR over the last five years
Simply Wall St. via Yahoo Finance· 11 months agoAbbVie Inc. (NYSE:ABBV) shareholders might be concerned after seeing the share price drop 16% in the...